Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | TASP1 | Q9H6P5 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22999953 | 0.83 | KDM4E (0.72) | ALDH1A1TP53CYP2C9HPGDALOX15 | |
| SCHEMBL23000006 | 0.75 | KDM4E (0.62) | ALDH1A1TP53CYP2C9HPGDALOX15 | |
| SCHEMBL28803540 | 0.73 | ALDH1A1 (0.57) | ALDH1A1TP53CYP2C9HPGDALOX15 | |
| SCHEMBL3056859 | 0.72 | MAPT (0.74) | ALDH1A1TP53CYP2C9HPGDALOX15 | |
| Arsanilic Acid SCHEMBL160507 | 0.70 | KDM4E (1.00) | ALDH1A1TP53CYP2C9HPGDALOX15 | |
| SCHEMBL20916722 | 0.70 | KDM4E (0.56) | ALDH1A1TP53CYP2C9HPGDALOX15 | |
| SCHEMBL11078484 | 0.70 | TSHR (0.56) | ALDH1A1TP53CYP2C9HPGDALOX15 | |
| SCHEMBL20916723 | 0.70 | KDM4E (0.56) | ALDH1A1TP53CYP2C9HPGDALOX15 | |
| Arsanilic Acid SCHEMBL4837583 | 0.70 | KDM4E (1.00) | ALDH1A1TP53CYP2C9HPGDALOX15 | |
| SCHEMBL11034243 | 0.70 | TSHR (0.56) | ALDH1A1TP53CYP2C9HPGDALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4057813-A1 | COMPOSITIONS AND METHODS FOR TREATING HUANGLONGBING DISEASE IN CITRUS | New Life Crop Sciences LLC (US) | 2022-09-21 | — | — | EP | claimed |
| WO-2021097410-A1 | COMPOSITIONS AND METHODS FOR TREATING HUANGLONGBING DISEASE IN CITRUS | NEW LIFE CROP SCIENCES LLC (US) | 2021-05-20 | — | — | WO | claimed |
| US-20210144998-A1 | COMPOSITIONS AND METHODS FOR TREATING HUANGLONGBING DISEASE IN CITRUS | NEW LIFE CROP SCIENCES LLC | 2021-05-20 | — | — | US | claimed |
| US-9504729-B2 | Antiangiogenic small molecules and methods of use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-11-29 | — | — | US | claimed |
| US-20160030508-A1 | ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2016-02-04 | — | — | US | claimed |
| US-9186365-B2 | Antiangiogenic small molecules and methods of use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-11-17 | — | — | US | claimed |
| EP-2461806-A2 | ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) | 2012-06-13 | — | — | EP | claimed |
| US-20120129775-A1 | ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2012-05-24 | — | — | US | claimed |
| EP-4057813-A1 | COMPOSITIONS AND METHODS FOR TREATING HUANGLONGBING DISEASE IN CITRUS | New Life Crop Sciences LLC (US) | 2022-09-21 | — | — | EP | disclosed |
| US-20210144998-A1 | COMPOSITIONS AND METHODS FOR TREATING HUANGLONGBING DISEASE IN CITRUS | NEW LIFE CROP SCIENCES LLC | 2021-05-20 | — | — | US | disclosed |
| US-9504729-B2 | Antiangiogenic small molecules and methods of use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-11-29 | — | — | US | disclosed |
| US-20160030508-A1 | ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2016-02-04 | — | — | US | disclosed |
| US-9186365-B2 | Antiangiogenic small molecules and methods of use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-11-17 | — | — | US | disclosed |
| US-8501811-B2 | TASPASE1 inhibitors and their uses | WASHINGTON UNIVERSITY (US) | 2013-08-06 | — | — | US | disclosed |
| EP-2461806-A2 | ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) | 2012-06-13 | — | — | EP | disclosed |
| US-20120129775-A1 | ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2012-05-24 | — | — | US | disclosed |
| US-20120015990-A1 | TASPASE1 INHIBITORS AND THEIR USES | THE WASHINGTON UNIVERSITY (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160030508-A1 | ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE | VEGFA, FLT4, KDR | ALDH1A1 1615/4885TP53 356/4885CYP2C9 4864/4885 |
| US-20120129775-A1 | ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE | VEGFA, FLT4, KDR | ALDH1A1 1615/4885TP53 356/4885CYP2C9 4864/4885 |
| US-20210144998-A1 | COMPOSITIONS AND METHODS FOR TREATING HUANGLONGBING DISEASE IN CITRUS | PNPO, G6PD, AGXT | ALDH1A1 2196/4885TP53 1665/4885CYP2C9 775/4885 |
| US-20120015990-A1 | TASPASE1 INHIBITORS AND THEIR USES | RNASE1, TASP1, PPA1 | ALDH1A1 3123/4885TP53 133/4885CYP2C9 4517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.